Clinical Trial Update: Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluated the safety and efficacy of a topical ranpirnase formulation for treating genital warts caused by human papillomavirus (HPV…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Condylomata Acuminata
• Human Papillomavirus Infection

Drugs mentioned

• Ranpirnase (ranpirnase)

Snippet

Sponsor: Tamir Biotechnology, Inc. | Conditions: Condylomata Acuminata, Papillomavirus Infections | Phase 1, Phase 2 | Status: COMPLETED